Manon Pillai

526 total citations
24 papers, 392 citations indexed

About

Manon Pillai is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Manon Pillai has authored 24 papers receiving a total of 392 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 8 papers in Economics and Econometrics. Recurrent topics in Manon Pillai's work include Renal cell carcinoma treatment (12 papers), Cancer Immunotherapy and Biomarkers (9 papers) and CAR-T cell therapy research (8 papers). Manon Pillai is often cited by papers focused on Renal cell carcinoma treatment (12 papers), Cancer Immunotherapy and Biomarkers (9 papers) and CAR-T cell therapy research (8 papers). Manon Pillai collaborates with scholars based in United Kingdom, United States and Canada. Manon Pillai's co-authors include Fiona Thistlethwaite, Robert E. Hawkins, Н. А. Кириллова, Ryan D. Guest, Surinder K. Sharma, Dominic G. Rothwell, Susan Wan, Sarah Halford, Juan W. Valle and Eric Austin and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Manon Pillai

21 papers receiving 388 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Manon Pillai United Kingdom	7	359	137	135	93	82	24	392
Su Jingwen China	6	353 1.0×	107 0.8×	230 1.7×	109 1.2×	70 0.9×	7	430
Marjan Zaman United States	6	316 0.9×	132 1.0×	128 0.9×	85 0.9×	78 1.0×	8	393
Daijing Yuan China	7	314 0.9×	78 0.6×	149 1.1×	114 1.2×	39 0.5×	10	402
Laurence C. Chen United States	3	297 0.8×	125 0.9×	153 1.1×	113 1.2×	65 0.8×	4	362
Yonggui Tian China	7	280 0.8×	70 0.5×	167 1.2×	126 1.4×	64 0.8×	8	377
Stephen Nabarro United Kingdom	6	331 0.9×	127 0.9×	183 1.4×	91 1.0×	82 1.0×	6	421
Daniel Michaud United States	7	384 1.1×	85 0.6×	313 2.3×	117 1.3×	57 0.7×	11	527
Enrico Fritsche Germany	7	262 0.7×	124 0.9×	125 0.9×	149 1.6×	66 0.8×	7	405
Soyeon Kim United States	5	570 1.6×	177 1.3×	287 2.1×	142 1.5×	153 1.9×	5	613
Caiying Jiang China	5	236 0.7×	55 0.4×	130 1.0×	61 0.7×	58 0.7×	7	277

Countries citing papers authored by Manon Pillai

Since Specialization

Citations

This map shows the geographic impact of Manon Pillai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manon Pillai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manon Pillai more than expected).

Fields of papers citing papers by Manon Pillai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manon Pillai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manon Pillai. The network helps show where Manon Pillai may publish in the future.

Co-authorship network of co-authors of Manon Pillai

This figure shows the co-authorship network connecting the top 25 collaborators of Manon Pillai. A scholar is included among the top collaborators of Manon Pillai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manon Pillai. Manon Pillai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McCarthy, Elizabeth, Amy L. Chadwick, J.J. Soto Castillo, et al.. (2025). A multi-centre review of the use of adjuvant pembrolizumab for renal cell carcinoma.. Journal of Clinical Oncology. 43(5_suppl). 484–484.

Pillai, Manon, et al.. (2025). Fever‐Induced Heat Shock Protein‐70 Regulates Macrophage IL‐1β and IL‐10 Secretion During Mycobacterium tuberculosis Infection. European Journal of Immunology. 55(7). e51963–e51963.

Shohdy, Kyrillus S., et al.. (2025). Patient-specific HLA-I subtypes predict response to immune checkpoint blockade. OncoImmunology. 14(1). 2462386–2462386.

Kennedy, Oliver, Rebecca Lee, Safwaan Adam, et al.. (2024). Seasonal patterns in immunotherapy outcomes.. Journal of Clinical Oncology. 42(16_suppl). e14684–e14684. 1 indexed citations

Nathan, Paul, Natalie Charnley, John McGrane, et al.. (2024). A UK real-world observational study of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): Outcomes at 36 months post treatment initiation.. Journal of Clinical Oncology. 42(4_suppl). 386–386. 2 indexed citations

Wysocka, Magdalena, Oskar Wysocki, Manon Pillai, et al.. (2023). Meta-analysis informed machine learning: Supporting cytokine storm detection during CAR-T cell Therapy. Journal of Biomedical Informatics. 142. 104367–104367. 19 indexed citations

Shohdy, Kyrillus S., Manon Pillai, Ryan D. Guest, et al.. (2023). Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies. SHILAP Revista de lepidopterología. 4(3). 882–885. 3 indexed citations

Lagan, Jakub, Josephine H. Naish, Christopher S. Campbell, et al.. (2022). Acute and Chronic Cardiopulmonary Effects of High Dose Interleukin-2 Therapy: An Observational Magnetic Resonance Imaging Study. Diagnostics. 12(6). 1352–1352. 1 indexed citations

Pillai, Manon, Yi‐Zhou Jiang, Paul Lorigan, et al.. (2022). Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma.. PubMed. 12(8). 3967–3984. 7 indexed citations

10.

Allison, Jennifer, Sam Wong, Helen Wong, et al.. (2022). Tivozanib (T) as first-line (1L) treatment of metastatic renal cell carcinoma (mRCC): A real-world outcome review in North-West of England (NWE), UK.. Journal of Clinical Oncology. 40(6_suppl). 335–335. 1 indexed citations

11.

Venugopal, Balaji, Manon Pillai, Thomas Powles, et al.. (2021). Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes. Clinical Genitourinary Cancer. 20(1). 94–94.e10. 6 indexed citations

12.

Hawkins, Robert E., Yizhou Jiang, Paul Lorigan, et al.. (2021). Abstract LB150: Clinical Feasibility and Treatment Outcomes with Unselected Autologous Tumor Infiltrating Lymphocyte Therapy in Patients with Advanced Cutaneous Melanoma. Cancer Research. 81(13_Supplement). LB150–LB150. 2 indexed citations

13.

Allison, Jennifer, Natalie Charnley, Robert B. Stevenson, Tom Waddell, & Manon Pillai. (2021). Axitinib and avelumab (AA) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world outcome review in the Northwest of England, United Kingdom.. Journal of Clinical Oncology. 39(6_suppl). 294–294. 2 indexed citations

14.

Allison, Jennifer, Richard W. Griffiths, Tom Waddell, & Manon Pillai. (2021). Ipilimumab and nivolumab (I+N) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world review in North West of England, United Kingdom.. Journal of Clinical Oncology. 39(6_suppl). 295–295. 1 indexed citations

15.

Pillai, Manon, RE Hawkins, Ying Jiang, et al.. (2021). 1058P Treatment outcomes with unselected autologous tumor infiltrating lymphocytes (TILs) in patients (pts) with checkpoint inhibition–refractory advanced cutaneous melanoma. Annals of Oncology. 32. S882–S882. 1 indexed citations

16.

Pillai, Manon, Thomas Powles, Bernadett Szabados, et al.. (2020). A non-interventional retrospective study to describe early clinical experience with cabozantinib in patients with advanced renal cell carcinoma (aRCC) in the United Kingdom.. Journal of Clinical Oncology. 38(15_suppl). e17089–e17089. 2 indexed citations

17.

Pillai, Manon, et al.. (2019). T-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into future developments. Current Opinion in Oncology. 31(5). 430–438. 7 indexed citations

18.

Thistlethwaite, Fiona, David E. Gilham, Ryan D. Guest, et al.. (2017). The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunology Immunotherapy. 66(11). 1425–1436. 303 indexed citations

19.

Pillai, Manon, et al.. (2016). High-dose interleukin2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome. Journal for ImmunoTherapy of Cancer. 4(1). 67–67. 18 indexed citations

20.

Pillai, Manon, et al.. (2016). 10 year outcomes from a single-centre experience of sunitinib and pazopanib as first-line treatment of metastatic renal-cell carcinoma (mRCC).. Journal of Clinical Oncology. 34(15_suppl). e16085–e16085. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact